Journal article
DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation
Transplant infectious disease, Vol.16(1), pp.141-144
01/03/2014
DOI: 10.1111/tid.12177
PMCID: PMC4469988
PMID: 24383501
Abstract
Parainfluenza infection is a cause of significant morbidity and mortality in allogeneic hematopoietic stem cell transplant (HSCT) patients. DAS181 is a novel antiviral agent with activity against influenza and parainfluenza. We report the first 2 cases, to our knowledge, of successful DAS181 use in ventilated HSCT patients with severe parainfluenza lung disease.
Details
- Title: Subtitle
- DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation
- Creators
- S. Chalkias - Beth Israel Deaconess Medical CenterM.R. Mackenzie - Beth Israel Deaconess Medical CenterC. Gay - Beth Israel Deaconess Medical CenterC. Dooley - Beth Israel Deaconess Medical CenterF.M. Marty - Brigham and Women's HospitalR.B. Moss - Ansun BioPharmaT. Li - Ansun BioPharmaR.L. Routh - Ansun BioPharmaS.R. Walsh - Beth Israel Deaconess Medical CenterC.S. Tan - Beth Israel Deaconess Medical Center
- Resource Type
- Journal article
- Publication Details
- Transplant infectious disease, Vol.16(1), pp.141-144
- DOI
- 10.1111/tid.12177
- PMID
- 24383501
- PMCID
- PMC4469988
- ISSN
- 1398-2273
- eISSN
- 1399-3062
- Language
- English
- Date published
- 01/03/2014
- Academic Unit
- Iowa Neuroscience Institute; Internal Medicine
- Record Identifier
- 9984366287102771
Metrics
6 Record Views